Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter.

Minerva endocrinologica

Volumn 31, Issue 3, 2006, Pages 191-209

  Giusti, M ^a   Cappi, C ^a   Santaniello, B ^a   Ceresola, E ^a   Augeri, C ^a   Lagasio, C ^a   Minuto, F ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN;

AGED; ARTICLE; CASE CONTROL STUDY; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NODULAR GOITER; RETROSPECTIVE STUDY; THYROID GLAND; TREATMENT OUTCOME;

AGED; CASE-CONTROL STUDIES; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GOITER, NODULAR; HUMANS; IODINE RADIOISOTOPES; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID GLAND; THYROTROPIN; TREATMENT OUTCOME;

EID: 34250864380     PISSN: 03911977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)